Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

Authors Sharma R, Reddy HK, Sharma RK, Moazazi M, Elango L, Singh VN, Williams DK, Voelker DJ

Published 6 September 2010 Volume 2010:2 Pages 155—162


Review by Single-blind

Peer reviewer comments 2

Rakesh K Sharma1, Hanumanth K Reddy1, Rohit K Sharma1, Mathilde Moazazi1, Lovett Elango1, Vibhuti N Singh2, D Keith Williams1, Donald J Voelker1
1Medical Center of South Arkansas, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Bayfront Medical Center, St Petersburg, FL, USA
Abstract: The potential interaction between clopidogrel and proton pump inhibitors (PPI) in patients with acute coronary syndrome (ACS) raises serious concerns for cardiologists. However, in patients on this combination of drugs, there is no conclusive evidence of an increase in adverse cardiovascular events. From pharmacologic and pharmacodynamic perspectives, there is a real interaction between clopidogrel and PPIs because of the competitive inhibition of CYP2C19 isoenzyme which is required for biotransformation of clopidogrel to its active metabolite. The consequent decrease in the availability of this active metabolite leads to attenuation of antiplatelet efficacy of clopidogrel. In several observational trials, it was shown that decreased antiplatelet effect of clopidogrel due to PPIs may translate into poor cardiovascular outcomes. However, an incomplete RCT (COGENT) and a post hoc analysis of two large trials (PRINCIPLE-TIMI 44 and TRITON-TIMI 38 trial) showed no significant adverse cardiovascular events with this combination. Caution is however needed in patients who are hypometabolizers of clopidogrel putting them at a higher risk of adverse coronary events. Since 3% of patients are likely to be hypometabolizers of clopidogrel, routine combination of clopidogrel and PPIs should be avoided. There is a heightened awareness of this interaction following multiple advisory warnings. At the same time, one should not withhold PPIs in patients who are at a high risk of developing gastrointestinal (GI) bleeding. In these patients, selected choices of PPI such as pantoprazole may be helpful and for low risk patients, serious consideration should be given to H2 receptor antagonists or antacids. Therefore, while not compromising the cardioprotective effect of antiplatelet agents, the gastroprotective benefit of PPI should be strongly considered in patients who need both. Health care providers should remain alert to more outcome data. Future researchers will need to demonstrate the safety of coadministration of PPIs and clopidogrel and trials should be powered to detect major adverse cardiovascular events and facilitate risk stratification based on genetic polymorphism.
Keywords: clopidogrel, proton pump inhibitors (PPIs), acute coronary syndrome (ACS), cardiovascular events, anti-platelet agents

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD

Vascular Health and Risk Management 2013, 9:187-193

Published Date: 1 May 2013

Understanding the application of stem cell therapy in cardiovascular diseases

Sharma RK, Voelker DJ, Sharma R, Reddy HK

Stem Cells and Cloning: Advances and Applications 2012, 5:29-37

Published Date: 30 October 2012

Evolving role of platelet function testing in coronary artery interventions

Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD

Vascular Health and Risk Management 2012, 8:65-75

Published Date: 8 February 2012

Cardiac risk stratification: Role of the coronary calcium score

Rakesh K Sharma, Rajiv K Sharma, Donald J Voelker, et al

Vascular Health and Risk Management 2010, 6:603-611

Published Date: 14 July 2010

Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”

Rakesh K Sharma, Donald J Voelker, Rajiv K Sharma, et al

Vascular Health and Risk Management 2010, 6:307-316

Published Date: 10 May 2010

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

Rakesh K Sharma, Hanumanth K Reddy, Vibhuti N Singh, et al

Vascular Health and Risk Management 2009, 5:965-972

Published Date: 9 November 2009

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk

Rakesh K Sharma, Vibhuti N Singh, Hanumanth K Reddy

Vascular Health and Risk Management 2009, 5:793-799

Published Date: 21 September 2009

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010